Table 1

Variables	
Sex (female),n (%)	76 (91.6)
Age (years),median(IQR)	41 (18)
Race,n(%)	
White	12 (14.5)
Black	55 (66.3)
Asiatic	6 (7.2)
Other	10 (12)
Smoker,n(%)	13 (15.6)
Duration of the disease (months),median(IQR)	116 (112)
SLEDAI,median(IQR)	2 (4)
ESR,median(IQR)	25 (42.5)
CRP,median(IQR)	2 (7.32)
ANA,n(%)	82 (98.8)
dsDNA,n(%)	36 (46.8)
Anti-SM,n(%)	37 (44.6)
AntiRNP,n(%)	41 (49.4)
Anti-SSA 52 kD,n(%)	18 (26.9)
Anti-SSA 60 kD,n(%)	29 (43.3)
Anti-SSB,n(%)	14 (16.9)
Anti cardiolipin,n(%)	17 (20.5)
Anticoagulate lúpico,n(%)	7 (8.4)
Anti Beta-2-gicoproteina,n(%)	1 (1.2)
Treatments	n (%)
HCQ	83 (64.3)
MTX	9 (10.8)
AZA	11 (13.3)
CF	1 (1.2)
Micofenolic acid	25 (30.1)
Steroids	41 (49.4)
Rituximab	3 (3.6)
Mepacrine	3 (3.6)

Results: A total of 129 patients with SLE were included. Clinical characteristics in Table 1. 38 patients (29.5%) had some degree of major depression and 27 (20.9%) generalized anxiety disorder (Table 2). The prevalence of major depression was higher in patients with anti RO52 (42.3% vs 23.8%, $p=0.06$), with generalized anxiety (81.5% vs 15.7%, $p<0.001$) and in patients with black (35.2% vs 17.1%, $p=0.03$). The prevalence of generalized anxiety was higher in smokers (35% vs 18.3%, $p=0.09$), patients receiving antidepressant treatment (57.1% vs 13.9%, $p<0.001$) and patients taking azathioprine (36.8% vs 18.2%, $p=0.06$). The prevalence of both major was higher in those who had higher fatigue and VAS higher (mean 67.1 vs 44.8 and 60.8 vs 32.3 in major depression, respectively; $p<0.001$) (65.3 vs 48.1 and 60.74 vs 35.4 in generalized anxiety respectively, $p<0.001$). The SLEDAI, ESR, duration of the disease and age were associated with generalized anxiety in a non-significant way. CRP, ESR and the duration of the disease were higher in patients with major depression.

Table 2

Variables	n (%)
Previous depression	23 (17.8)
Antidepressants	17 (13.2)
GAD 7 total	
>15: Severe Anxiety Disorder	20 (15.5)
>10: Moderate Anxiety Disorder	7 (5.4)
>5: Mild anxiety disorder	12 (9.3)
PHQ 9 total	
>20: Severe major depression	11 (8.5)
>15: Moderately Severe Depression	20 (15.5)
>10: Moderate major depression	7 (5.4)
>5: Mild depression	7 (5.4)

Conclusion: The prevalence of anxiety and depression in our group of patients was high, both related, as well as with the perception of pain and fatigue. A correct assessment of these manifestations and early treatment could help improve the quality of life of patients.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2019-eular.5022

AB0554

RISK OF CORONARY ARTERY DISEASE AND STROKE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS USING JAPANESE HEALTH INSURANCE DATABASE

Ryoko Sakai, Suguru Honda, Sho Suzuki, Masako Majima, Naoko Konda, Hideto Takada, Masayoshi Harigai, Hisashi Yamanaka. Tokyo Women's Medical University, 1. Department of Rheumatology, Tokyo, Japan

Background: Patients with systemic lupus erythematosus (SLE) have higher risk of coronary artery disease (CAD) and stroke than the general population¹⁻². Because these comorbidities influence on patients' vital prognosis and quality of life, it is essential for rheumatologists to manage them appropriately. Considering differences in life style and ethnicity, it is of great interest and needed to investigate risk of these comorbidities in Asia. However, to date, such evidence is scarce.

Objectives: To estimate incidence rate (IR) and identify risk factors of CAD and stroke in patients with SLE using a Japanese health insurance database.

Methods: This retrospective longitudinal population-based study was conducted using claims data provided by Medical Data Vision Co., Ltd (Tokyo, Japan). We defined individuals as SLE cases if they met all of the following: 1) had at least one ICD10 code (M321 or M329); 2) had at least one prescription of oral corticosteroids (CS), methylprednisolone (mPSL) pulse therapy, immunosuppressive drugs (IS) (azathioprine, mizoribine, tacrolimus, mycophenolate mofetil, cyclophosphamide, methotrexate), biologics (belimumab, rituximab) or hydroxychloroquine between April 2008 and July 2017; 3) were 16 years old or over. The start of observation was defined by the first month in which cases met all of the above criteria. Patients were followed until the earliest of date of first CAD event or stroke, date of loss of follow-up, or the end of follow-up (June 2018). CAD and stroke were defined as follows: for CAD, at least one ICD10 code (I20.x or I21.x or I23-24.x) and either percutaneous coronary intervention, coronary artery bypass procedure, or thrombolytic agents during hospitalization; for stroke, at least one ICD10 code (I60-62.x or I63-64.x) and either cerebrovascular procedures, thrombolytic agents, or antiplatelet drugs during hospitalization. Patients were excluded if they had a previous diagnosis of CAD or stroke and were prescribed antiplatelet drugs or anticoagulants during the first 3 months. We defined baseline characteristics using the data from the first 3 months, and calculated IR and adjusted hazard ratio (HR) of risk factors for CAD or stroke after adjusting for baseline characteristics using a Cox proportional hazard model.

Results: In this study, 19,138 cases were included. The median age was 53 years and 81.3% were female. Median observation period was 3.1 years. IR [95% CI]/1,000 patient-years (PY) of CAD or stroke was 1.41 [1.11-1.77] and 4.10 [3.56-4.70], respectively. IR of any CAD or stroke was increased age-dependently (2.06 [1.47-2.80] for 16-39 years-old, 5.07 [4.36-5.86] for 40-69, 13.0 [10.9-15.5] for 70+). Adjusted HR [95% CI] was 1.37 [95% CI, 1.27-1.47] for age by decade, 3.34 [1.78-6.28] for CS use, 1.46 [1.16-1.84] for presence of hypertension (HT), 1.38 [1.04-1.85] for diabetes mellitus (DM), 1.73 [1.25-2.38] for chronic kidney disease (CKD), and 1.95 [1.15-3.32] for atrial fibrillation (AF).

Conclusion: This is the first study investigating the risk of CAD or stroke in Japanese patients with SLE using a large health insurance database. Older age, use of CS, and presence of HT, DM, CKD, and AF were identified as significant risk factors of these comorbidities.

REFERENCES

- Am J Cardiol. 2004;198-200
- Arthritis Rheum 2009;1396-1402

Disclosure of Interests: Ryoko Sakai Grant/research support from: Tokyo Women's Medical University (TWMU) has received unrestricted research grants for

Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases from Ayumi Pharmaceutical Co. Ltd., Bristol Meyers Squibb, Chugai Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp., and with which TWMU paid the salary of R.S. RS has received a research grant from Bristol-Meyers Squibb., Suguru Honda: None declared, Sho Suzuki: None declared, masako majima: None declared, naoko konda: None declared, hideto takada: None declared, masayoshi harigai Grant/research support from: Tokyo Women's Medical University (TWMU) has received unrestricted research grants for

Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases from Ayumi Pharmaceutical Co. Ltd., Bristol Meyers Squib, Chugai Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp., and with which TWUMU paid the salary of MH. MH has also received research grants from AbbVie Japan GK, Eisai Co. Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd., Hisashi Yamanaka Grant/research support from: AbbVie, Eisai, Bristol-Meyers, Novartis, Behringer, Astellas, Kaken, Nippon-Shinyaku, Pfizer, UCB, Ayumi, Ono, Daiichi-Sankyo, Taisyo-Toyama, Takeda, Tanabe-Mitsubishi, Chugai, Teijin Pharma, Torii, YLbio, Speakers bureau: Bristol-Meyers, Astellas, Pfizer, Daiichi-Sankyo, Takeda, Tanabe-Mitsubishi, Chugai, Teijin Pharma, YLbio
DOI: 10.1136/annrheumdis-2019-eular.4439

AB0555 POTENTIAL ROLE OF PAROTID ELASTOGRAPHY IN DIAGNOSIS AND CLASSIFICATION OF PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME

Hasan Satis¹, Betül Nur Demir², Reyhan Bilici Salman¹, Esra Temel², Hakan Babaoglu¹, Nuh Atas¹, Aslıhan Avanoğlu Güler¹, Hazan Karadeniz¹, Emetullah Cingil², Abdurrahman Tufan¹, Mehmet Akif Öztürk¹, Semir Haznedaroglu¹, Berna Göker¹. ¹Gazi University Faculty of Medicine, Rheumatology, Ankara, Turkey; ²Gazi University Faculty of Medicine, Radiology, Ankara, Turkey

Background: Despite the improvements in classifying patients with primary Sjögren's syndrome with usage of the new 2016 ACR/EULAR classification criteria, there remains to be a need for improvement and investigating the value of new modalities in diagnosing as well as classifying these patients.

Objectives: to investigate potential role of parotid elastography in diagnosis and classification of patients with primary Sjögren's syndrome (pSS)

Methods: This is a cross sectional analysis of patients with primary Sjögren's syndrome followed up in our out-patient Rheumatology clinic. We performed chart reviews and retrospectively investigated the available data on files to search whether or not our clinically diagnosed patients satisfied the 2002 AEG and/or 2016 ACR/EULAR criteria sets. Ultrasonographic and elastographic evaluation of parotid and submandibular glands bilaterally were performed on consecutive patients with clinical diagnosis of pSS and contributions of these findings to classification criteria sets were interpreted

Results: There were 95 pSS patients and 30 healthy gender and age matched controls. Strain ratio, shearwave velocity and Pascal values of the glands were examined. Parotid strain ratio, submandibular velocity and submandibular pascal values were statistically significantly different compared to healthy controls (Table).%86 of patients considered clinically as Sjögren syndrome satisfied 2016 ACR/EULAR (criteria patients) and% 84 satisfied 2002 AER classification criteria. We grouped patients with respect to parotid strain ratio taking 1.0875 as the cut-off value. Those patients who did not satisfy 2016 ACR/EULAR criteria, but clinically diagnosed as pSS (non criteria pSS patients), also had significantly higher parotid strain ratio and submandibular velocity compared to healthy controls (p:0,016 and p<0,001 respectively). Interestingly, both criteria and non-criteria pSS patients had similar parotid strain ratio and submandibular velocity value (p:0,892 and p:0,260, respectively)

Conclusion: Parotid shear elastography is an easy and noninvasive method and can be a useful tool for the diagnosis and classification of patients with pSS (1).

REFERENCES

- [1] Mossel E, Delli K, van Nimwegen JF, Stel AJ, Kroese FGM, Spijkervet FKL, Vissink A, Arends S, Bootsma H; EULAR US-pSS Study Group. Ultrasonography of major salivary glands compared with parotid and labial gland biopsy and classification criteria in patients with clinically suspected primary Sjögren's syndrome Ann Rheum Dis. 2017 Nov;76(11):1883-1889. doi: 10.1136/annrheumdis-2017-211250

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.6036

AB0556 PARTICULARITIES OF PULMONARY HYPERTENSION IN SYSTEMIC LUPUS ERYTHEMATOSUS

sameh sayhi, Nouha Ghriss, Najeh Boussetta, Bilel Arfaoui, Faïda Ajili, Nadia Ben Abdelhafidh, Bassem Louzir. *Military Hospital of Tunis, Autoimmune Diseases Unit Research: UR17DN02, Tunis, Tunisia*

Background: Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects young women. It is characterized by the production of autoantibodies and immune complexes. Vascular pulmonary involvement has long been considered rare, a consequence of thromboembolic events. It is in fact a proper entity, often of multifactorial mechanism, with spontaneous evolution to pulmonary arterial hypertension (PAH), which makes its gravity

Objectives: The objective of our study is to determine the particularities of PAH during SLE.

Methods: We conducted a mono-centric, retrospective and descriptive study of the follow up of patients in the internal medicine department of the Military Hospital of Tunis for LES (diagnosis according to the ARA criteria) between January 2010 and December 2015.

All patients underwent external echocardiography or during their stay in the department

Results: We collected 87 patients diagnosed with SLE. PAH was recorded in 16 patients (38%) including 6 men and 10 women with a F/M sex ratio of 1.66. The average age was 37.23 years with extremes ranging from 16 to 70 years old. Clinically, we observed dyspnea in 10 patients (62%), chest pain in 7 cases (43%), dry cough in 2 cases (12%), palpitations in 1 case (6%), and right heart failure in 1 case (6%). At cardiac auscultation, 5 patients were tachycardic (31%), 5 had a tricuspid systolic murmur and 1 had an irregular rhythm. A burst of B2 in the pulmonary focus was noted in 3 patients (18%). Nine of the 16 patients with PAH had electrical signs: five had sinus tachycardia (31%), two had signs of right ventricular hypertrophy. A complete arrhythmia with atrial fibrillation was noted in one patient. The chest X-ray showed cardiomegaly in 6 patients (37%). Among the 16 patients, there was a tricuspid valve insufficiency associated with PAH in 7 patients (43%), 2 had mitral valve insufficiency (12%), 6 patients had pericarditis, one patient had endocarditis (6%) and myocarditis was found in another one (6%). PAH was isolated in 12% of cases. In Immunological tests, NAAs were positive in all patients. Three quarters of the patients (12) had native anti-DNA positive (75%) and ¼ of the patients (4) had anti-Sm positive and anti-RNP positive antibodies (25%). The complement was consumed in 5 cases (31.2%). Anti-phospholipid antibodies were noted in 4 cases (25%). Added to non-specific measures (smoking cessation, elimination of intense physical effort ...) adopted for all patients, oxygen therapy was indicated in four patients. Diltiazem 180 mg/day vasodilator therapy was prescribed in 3 patients. Effective anti-vitamin K anticoagulation was prescribed in a patient with severe PAH at 80 mmHg.

Conclusion: Pulmonary arterial hypertension (PAH) is a rare complication of systemic lupus erythematosus, its prevalence varies from 0.5 to 17.5% depending on the series. SLE is the second leading cause of PAH in connective tissue disease after systemic sclerosis. This vascular involvement is essential for the prognosis and is an important evolutionary step in the management.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.8162

AB0557 NON-CORONARY CARDIAC MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS IN ADULTS

Nouha Ghriss, sameh sayhi, Najeh Boussetta, Nour El Houda Gueddich, Faïda Ajili, Nadia Ben Abdelhafidh, Bassem Louzir. *military hospital, autoimmune diseases unit research: UR17DN02, tunis, Tunisia*

Background: Systemic lupus erythematosus (SLE) is a common chronic multi-system autoimmune disorder of unknown etiology causing injury to many organ Systems. It predominantly affects young women. Cardiac manifestations develop in the majority of patients with SLE at some time during the course of their disease.

Objectives: The aim of our study is to assess cardiac abnormalities in patients with systemic lupus erythematosus (SLE) by echocardiography and to compare the 2 groups of patients with and without cardiac manifestations.

Methods: We have performed a transversal, descriptive study of SLE patients hospitalized in the Internal Medicine department at the Military Hospital of Tunis between January 2016 and June 2018. Diagnosis of SLE was made according to the criteria of ACR. All patients underwent a cardiac ultrasound externally or during their stay in our department.